CoChat
Sign Up
Cited by 0Cardiomyopathy and Myosin StudiesHeart Failure Treatment and ManagementCardiovascular Function and Risk Factors

The DOI matches its Crossref record.

Concomitant GLP-1 Receptor Agonist Therapy Is Associated With Significant Weight Reduction In Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten

Duqueney, Estherland, Reza, Nosheen, Mahmud, Nadim, Austin, Melissa, Patel, Parth, Boakye, Ellen, De Feria, Alejandro, Hornsby, Nicole, Marzolf, Amy, Owens, Anjali·2026·Journal of Cardiac Failure
DOI 10.1016/j.cardfail.2025.11.294
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/j.cardfail.2025.11.294

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Still being checked.

Cited by

Still being checked.

Related

Metadata

Authors
Duqueney, E., Reza, N., Mahmud, N., Austin, M., Patel, P., Boakye, E., De Feria, A., Hornsby, N., Marzolf, A., & Owens, A.
Affiliations
  • Leonard Davis Institute of Health Economics (US)
  • University of Pennsylvania Health System (US)
  • Hospital of the University of Pennsylvania (US)
  • University of Pennsylvania (US)
ORCID
Venue
Journal of Cardiac Failure
Publisher
Elsevier BV
Published
2026-01
Volume
32
Issue
1
Pages
290
ISSN
1071-9164 (ISSN-L)
DOI
10.1016/j.cardfail.2025.11.294
OpenAlex
W7123355633
Cited by
0
References
0
FWCI
0.00
Type
journal article
Language
en
Open access
closed
Licence
Locations
Journal of Cardiac Failure (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
Keywords
hypertrophic obstructive cardiomyopathy, mavacamten, GLP-1 receptor agonists, weight loss, obesity, body mass index, cardiac myosin inhibitor, concomitant medications, left ventricular outflow tract gradient, cardiometabolic comorbidities, atrial fibrillation, hypertension, obstructive coronary artery disease, Valsalva maneuver

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review